COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study to Evaluate the Effects of Neramexane on the Pharmacokinetics of a Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Healthy Female Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00915174
Recruitment Status : Completed
First Posted : June 5, 2009
Last Update Posted : May 6, 2011
Information provided by:
Merz Pharmaceuticals GmbH

Brief Summary:


To assess the effects of repeated dose of Neramexane on the steady-state pharmacokinetics of Drospirenone [DRSP] and Ethinyl Estradiol [EE]


To assess safety and tolerability of concomitant repeated dose treatments of Neramexane and a fixed-combinational DRSP- and EE-containing oral contraceptive [OC] (Yasmin®)

Condition or disease Intervention/treatment Phase
Healthy Drug: Neramexane Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Study Start Date : June 2009
Actual Primary Completion Date : November 2009
Actual Study Completion Date : November 2009

Intervention Details:
  • Drug: Neramexane
    25 mg q.d., 3 days 2 x 25 mg b.i.d., 11 days

Primary Outcome Measures :
  1. Area Under Curve within a dose interval (AUC, 0-tau) and Maximum Plasma Concentration at Steady State (Cmax) of Drospirenone (DRSP) and Ethinyl Estradiol (EE) [ Time Frame: 24 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy adult female subject of child bearing potential (including subject with tubal ligation), white origin, who is able to read, to write and fully understand German language
  • Aged 18 to 45 years (both inclusive)
  • BMI of 18-28 kg/m2 and a body weight of 50-90 kg (both inclusive)
  • The subject is required
  • To have taken a DRSP/EE- containing OC for at least two dosing cycles
  • To agree using reliable non hormonal birth control methods from Day -1 of study Period 1 until the Final Examination (e.g. non-hormonal IUD, double barrier method [e.g. condom with spermicide or diaphragm with spermicide], sexual abstinence). Women with tubal ligation or sterilized partner do not need an additional birth control method
  • Willing and able to provide written informed consent after having been informed of the requirements and the restrictions of the study

Exclusion Criteria:

  • History of clinically relevant allergy or known hypersensitivity to Neramexane/Memantine/ Amantadine and their derivatives
  • Hypersensitivity to Quinine
  • History of clinically relevant allergy or known hypersensitivity to any inactive ingredient in any of the used study medications (Neramexane, Yasmin®, Placebo) or tool substance
  • History of clinically relevant allergy or known hypersensitivity to DRSP/EE
  • Clinically relevant findings on the mammae or genital examination, PAP smear ≥ III
  • Any contraindications against the oral contraceptive:
  • present or past venous thromboses (deep vein thrombosis, pulmonary embolism);
  • present or past arterial thromboses (e.g. myocardial infarction) or their prodromal stages (e.g. angina pectoris and transitory ischaemic attack);
  • present or past cerebrovascular insult;
  • presence of a serious risk factor or several risk factors for an arterial thrombosis: diabetes mellitus with vascular changes, severe hypertension, severe lipid metabolism disturbance;
  • known or suspected genetic or acquired predisposition for venous or arterial thromboses like APC resistance,
  • known or suspected genetic lack of antithrombin III, lack of protein C, lack of protein S, hyperhomocysteinaemia and antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulants);
  • present or past pancreatitis if this is accompanied by severe hypertriglyceridaemia;
  • present or past severe hepatic disease as long as the liver function tests have not normalized;
  • severe renal insufficiency or acute renal failure;
  • present or past hepatic tumors (benign or malign);
  • known or suspected sexual hormone dependent, malign tumors (e.g. of the genital organs or the mamma);
  • diagnostic not clarified vaginal bleedings;
  • anamnesis of migraine with focal neurologic symptoms;
  • known hereditary angioedema
  • Exposure to another investigational agent within the last two months before Day 1 of Period 1

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00915174

Layout table for location information
AAIharma Deutschland GmbH & Co. KG
Neu Ulm, Bavaria, Germany, 89231
Sponsors and Collaborators
Merz Pharmaceuticals GmbH
Layout table for investigator information
Study Director: Medical Expert Merz Pharmaceuticals
Layout table for additonal information
Responsible Party: Manager Public Disclosure, Merz Pharmaceuticals GmbH Identifier: NCT00915174    
Other Study ID Numbers: MRZ 92579/TI/1005
First Posted: June 5, 2009    Key Record Dates
Last Update Posted: May 6, 2011
Last Verified: May 2011
Keywords provided by Merz Pharmaceuticals GmbH:
drug-drug interaction study